Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Keeping children with exercise-induced asthma active.

H Milgrom1, L M Taussig

  • 1Department of Pediatrics, National Jewish Medical and Research Center and the University of Colorado Health Sciences Center, Denver, Colorado 80206, USA. milgromh@njc.org

Pediatrics
|September 2, 1999
PubMed
Summary

Exercise-induced asthma (EIA) causes temporary airway obstruction during physical activity. Prophylactic medication, like short-acting beta-agonists or long-acting bronchodilators, effectively prevents EIA symptoms in athletes and children.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumors of the skin. VI. Study on effects of local administration of 5-fluorouracil in basal cell carcinoma.

The Journal of investigative dermatology·2015
Same author

International consensus on (ICON) pediatric asthma.

Allergy·2012
Same author

Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.

Clinical pediatrics·2009
Same author

Dynamic changes in sensitization to specific aeroallergens in children raised in a desert environment.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2004
Same author

Anti-IgE therapy in children with asthma.

Minerva pediatrica·2004
Same author

Is there a role for treatment of asthma with omalizumab?

Archives of disease in childhood·2002

Area of Science:

  • Pulmonology
  • Sports Medicine
  • Pediatrics

Background:

  • Exercise-induced asthma (EIA), also known as exercise-induced bronchospasm, is a common condition causing temporary airflow obstruction during physical exertion.
  • It affects a significant percentage of individuals with asthma, allergic rhinitis, and even the general athletic population, often going undiagnosed.
  • Symptoms like shortness of breath and wheezing typically appear post-exercise, influenced by ventilation, heat, and water loss in the airways.

Purpose of the Study:

  • To review the prevalence, diagnosis, and management of exercise-induced asthma (EIA).
  • To highlight the importance of screening for EIA, even in seemingly healthy athletes.
  • To discuss pharmacologic therapies for preventing EIA symptoms.

Main Methods:

Related Experiment Videos

  • Review of existing literature on exercise-induced asthma (EIA).
  • Analysis of prevalence data in various populations, including athletes and children.
  • Evaluation of the efficacy of different pharmacologic interventions for EIA prevention.

    • Main Results:

    • EIA affects between 6-13% of the general population and up to 90% of asthmatics, frequently remaining undiagnosed.
    • A decrease in peak expiratory flow rate exceeding 15% post-exercise is diagnostic.
    • Pharmacologic therapies, including short-acting beta-agonists, long-acting bronchodilators, and cromolyn sodium, are effective in preventing EIA.

    Conclusions:

    • EIA is a prevalent condition that warrants screening, particularly in athletes and children.
    • Prophylactic treatment is effective for EIA, with long-acting medications potentially offering advantages for children.
    • Various medications can suppress EIA, with short-acting beta-agonists being a first-line therapy.